{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:37:58Z","timestamp":1784043478357,"version":"3.55.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12325-024-03009-2","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T05:17:29Z","timestamp":1731129449000},"page":"246-260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of Cariprazine on Anhedonia in Patients with Bipolar\u00a0I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct02670538","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02670551","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01396447","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Roger S.","family":"McIntyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Michel","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Aronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy-Binh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"key":"3009_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"1\u20132","key":"3009_CR2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.psychres.2008.05.003","volume":"30","author":"M Mazza","year":"2009","unstructured":"Mazza M, Squillacioti MR, Pecora RD, et al. Effect of aripiprazole on self-reported anhedonia in bipolar depressed patients. Psychiatry Res. 2009;30(1\u20132):193\u20136.","journal-title":"Psychiatry Res"},{"issue":"3","key":"3009_CR3","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/wps.20997","volume":"21","author":"RS McIntyre","year":"2022","unstructured":"McIntyre RS, Alda M, Baldessarini RJ, et al. The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management. World Psychiatry. 2022;21(3):364\u201387.","journal-title":"World Psychiatry"},{"issue":"4","key":"3009_CR4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00787-019-01364-y","volume":"29","author":"R Watson","year":"2020","unstructured":"Watson R, Harvey K, McCabe C, et al. Understanding anhedonia: a qualitative study exploring loss of interest and pleasure in adolescent depression. Eur Child Adolesc Psychiatry. 2020;29(4):489\u201399.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"3009_CR5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/7854_2022_323","volume":"58","author":"A Whitton","year":"2022","unstructured":"Whitton A, Pizzagalli DA. Anhedonia in depression and bipolar disorder. Curr Top Behav Neurosci. 2022;58:111\u201327.","journal-title":"Curr Top Behav Neurosci"},{"key":"3009_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eurpsy.2017.02.485","volume":"44","author":"F Vinckier","year":"2017","unstructured":"Vinckier F, Gourion D, Mouchabac S. Anhedonia predicts poor psychosocial functioning: results from a large cohort of patients treated for major depressive disorder by general practitioners. Eur Psychiatry. 2017;44:1\u20138.","journal-title":"Eur Psychiatry"},{"issue":"3","key":"3009_CR7","first-page":"120","volume":"11","author":"N Atre-Vaidya","year":"1998","unstructured":"Atre-Vaidya N, Taylor MA, Seidenberg M, et al. Cognitive deficits, psychopathology, and psychosocial functioning in bipolar mood disorder. Neuropsychiatry Neuropsychol Behav Neurol. 1998;11(3):120\u20136.","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"3009_CR8","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jad.2024.04.086","volume":"356","author":"S Wong","year":"2024","unstructured":"Wong S, Lee GH, Phan L, et al. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: a systematic review and meta-analysis. J Affect Disord. 2024;356:684\u201398.","journal-title":"J Affect Disord"},{"issue":"10265","key":"3009_CR9","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(20)31544-0","volume":"396","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Berk M, Brietzke E, et al. Bipolar disorders. Lancet. 2020;396(10265):1841\u201356.","journal-title":"Lancet"},{"key":"3009_CR10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jad.2017.04.057","volume":"18","author":"ED Ballard","year":"2017","unstructured":"Ballard ED, Wills K, Lally N, et al. Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. J Affect Disord. 2017;18:195\u2013200.","journal-title":"J Affect Disord"},{"issue":"5","key":"3009_CR11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/da.22709","volume":"35","author":"D Ducasse","year":"2018","unstructured":"Ducasse D, Loas G, Dassa D, et al. Anhedonia is associated with suicidal ideation independently of depression: a meta-analysis. Depress Anxiety. 2018;35(5):382\u201392.","journal-title":"Depress Anxiety"},{"key":"3009_CR12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jpsychires.2022.12.024","volume":"158","author":"ES Gillissie","year":"2023","unstructured":"Gillissie ES, Le GH, Rhee TG, et al. Evaluating anhedonia as a risk factor in suicidality: a meta-analysis. J Psychiatr Res. 2023;158:209\u201315.","journal-title":"J Psychiatr Res"},{"key":"3009_CR13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jpsychires.2020.12.031","volume":"134","author":"M Dimick","year":"2021","unstructured":"Dimick M, Hird M, Fiksenbaum LM, et al. Severe anhedonia among adolescents with bipolar disorder is common and associated with increased psychiatric symptom burden. J Psychiatr Res. 2021;134:200\u20137.","journal-title":"J Psychiatr Res"},{"issue":"2","key":"3009_CR14","doi-asserted-by":"crossref","first-page":"24com15322","DOI":"10.4088\/JCP.24com15322","volume":"85","author":"RS McIntyre","year":"2024","unstructured":"McIntyre RS. The co-occurrence of depression and obesity: implications for clinical practice and the discovery of targeted and precise mechanistically informed therapeutics. J Clin Psychiatry. 2024;85(2):24com15322.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"3009_CR15","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1017\/S1092852922001043","volume":"28","author":"MY Jawad","year":"2023","unstructured":"Jawad MY, Meshkat S, Tabassum A, et al. The bidirectional association of nonalcoholic fatty liver disease with depression, bipolar disorder, and schizophrenia. CNS Spectr. 2023;28(5):541\u201360.","journal-title":"CNS Spectr"},{"issue":"1\u20133","key":"3009_CR16","first-page":"446","volume":"147","author":"MR Di Nicola","year":"2012","unstructured":"Di Nicola MR, Luisa, Battaglia C, Camardese G, et al. Reduced hedonic capacity in euthymic bipolar subjects: a trait-like feature? J Affect Disord. 2012;147(1\u20133):446\u201350.","journal-title":"J Affect Disord"},{"issue":"3","key":"3009_CR17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neubiorev.2010.06.006","volume":"35","author":"MT Treadway","year":"2011","unstructured":"Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev. 2011;35(3):537\u201355.","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"3009_CR18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/ijnp\/pyy081","volume":"22","author":"A Hoflich","year":"2019","unstructured":"Hoflich A, Michenthaler P, Kasper S, et al. Circuit mechanisms of reward, anhedonia, and depression. Int J Neuropsychopharmacol. 2019;22(2):105\u201318.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"7","key":"3009_CR19","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1176\/appi.ajp.20220423","volume":"179","author":"DA Pizzagalli","year":"2022","unstructured":"Pizzagalli DA. Toward a better understanding of the mechanisms and pathophysiology of anhedonia: are we ready for translation? Am J Psychiatry. 2022;179(7):458\u201369.","journal-title":"Am J Psychiatry"},{"key":"3009_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neuroscience.2021.06.030","volume":"469","author":"CC-G Guo","year":"2021","unstructured":"Guo CC-G, Verheij MMM, Homberg JR. Knockout of the serotonin transporter in the rat mildly modulates decisional anhedonia. Neuroscience. 2021;469:31\u201345.","journal-title":"Neuroscience"},{"issue":"1","key":"3009_CR21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tins.2011.11.005","volume":"35","author":"A Der-Avakian","year":"2012","unstructured":"Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci. 2012;35(1):68\u201377.","journal-title":"Trends Neurosci"},{"key":"3009_CR22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-clinpsy-050212-185606","volume":"10","author":"DA Pizzagalli","year":"2014","unstructured":"Pizzagalli DA. Depression, stress, and anhedonia: toward a synthesis and integrated model. Annu Rev Clin Psychol. 2014;10:393\u2013423.","journal-title":"Annu Rev Clin Psychol"},{"issue":"12","key":"3009_CR23","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s12276-020-00532-4","volume":"52","author":"J-H Baik","year":"2020","unstructured":"Baik J-H. Stress and the dopaminergic reward system. Exp Mol Med. 2020;52(12):1879\u201390.","journal-title":"Exp Mol Med"},{"issue":"1","key":"3009_CR24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/ejn.13390","volume":"45","author":"P Sokoloff","year":"2017","unstructured":"Sokoloff P, Foll BL. The dopamine\u00a0D3 receptor, a quarter century later. Eur J Neurosci. 2017;45(1):2\u201319.","journal-title":"Eur J Neurosci"},{"issue":"3","key":"3009_CR25","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1124\/jpet.103.062463","volume":"309","author":"MJ Millan","year":"2004","unstructured":"Millan MJ, Brocco M, Papp M, et al. S32504, a novel naphtoxazine agonist at dopamine\u00a0D3\/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole. J Pharmacol Exp Ther. 2004;309(3):936\u201350.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"3009_CR26","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/BF02245568","volume":"115","author":"P Willner","year":"1994","unstructured":"Willner P, Lappas S, Cheeta S, et al. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology. 1994;115(4):454\u201362.","journal-title":"Psychopharmacology"},{"issue":"1\u20132","key":"3009_CR27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jns.2006.05.024","volume":"248","author":"MR Lemke","year":"2006","unstructured":"Lemke MR, Brecht HM, Koester J, et al. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson\u2019s disease. J Neurol Sci. 2006;248(1\u20132):266\u201370.","journal-title":"J Neurol Sci"},{"issue":"3","key":"3009_CR28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1176\/appi.ajp.2015.15020164","volume":"173","author":"S Durgam","year":"2016","unstructured":"Durgam S, Earley W, Lipschitz A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar\u00a0I depression. Am J Psychiatry. 2016;173(3):271\u201381.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"3009_CR29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bdi.12852","volume":"22","author":"WR Earley","year":"2020","unstructured":"Earley WR, Burgess MV, Khan B, et al. Efficacy and safety of cariprazine in bipolar\u00a0I depression: a double-blind, placebo-controlled phase\u00a03 study. Bipolar Disord. 2020;22(4):372\u201384.","journal-title":"Bipolar Disord"},{"issue":"6","key":"3009_CR30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1176\/appi.ajp.2018.18070824","volume":"176","author":"W Earley","year":"2019","unstructured":"Earley W, Burgess MV, Rekeda L, et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase\u00a03 study. Am J Psychiatry. 2019;176(6):439\u201348.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"3009_CR31","doi-asserted-by":"crossref","first-page":"24841","DOI":"10.4088\/PCC.20m02611","volume":"22","author":"LN Yatham","year":"2020","unstructured":"Yatham LN, Vieta E, McIntyre RS, et al. Broad efficacy of cariprazine on depressive symptoms in bipolar disorder and the clinical implications. Prim Care Companion CNS Disord. 2020;22(5):24841.","journal-title":"Prim Care Companion CNS Disord"},{"issue":"2","key":"3009_CR32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/YIC.0000000000000344","volume":"36","author":"M Patel","year":"2021","unstructured":"Patel M, Jain R, Tohen M, et al. Efficacy of cariprazine in bipolar\u00a0I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies. Int Clin Psychopharmacol. 2021;36(2):76\u201383.","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"3009_CR33","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/ijnp\/pyx038","volume":"20","author":"V Duric","year":"2017","unstructured":"Duric V, Banasr M, Franklin T, et al. Cariprazine exhibits anxiolytic and dopamine\u00a0D3 receptor-dependent antidepressant effects in the chronic stress model. Int J Neuropsychopharmacol. 2017;20(10):788\u201396.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5\u20136","key":"3009_CR34","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/FBP.0000000000000070","volume":"25","author":"M Papp","year":"2014","unstructured":"Papp M, Gruca P, Laso\u0144-Tyburkiewicz M, et al. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol. 2014;25(5\u20136):567\u201374.","journal-title":"Behav Pharmacol"},{"issue":"1","key":"3009_CR35","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","volume":"333","author":"B Kiss","year":"2010","unstructured":"Kiss B, Horv\u00e1th A, N\u00e9methy Z, et al. Cariprazine (RGH-188), a dopamine\u00a0D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328\u201340.","journal-title":"J Pharmacol Exp Ther"},{"key":"3009_CR36","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139.","journal-title":"Br J Psychiatry"},{"key":"3009_CR37","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revised. 2000."},{"issue":"Suppl 20","key":"3009_CR38","first-page":"20","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):20\u201333.","journal-title":"J Clin Psychiatry"},{"key":"3009_CR39","volume-title":"Structured clinical interview for DSM-IV-TR axis I disorders, clinical trials version (SCID-CT)","author":"MB First","year":"2007","unstructured":"First MB, Williams JBW, Spitzer RL, et al. Structured clinical interview for DSM-IV-TR axis I disorders, clinical trials version (SCID-CT). New York: Biometrics Research, New York State Psychiatric Institute; 2007."},{"issue":"1","key":"3009_CR40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50\u20135.","journal-title":"Br J Med Psychol"},{"key":"3009_CR41","first-page":"218","volume-title":"ECDEU assessment manual for psychopharmacology. US Dept Health, Education, and Welfare Publication (ADM)","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. US Dept Health, Education, and Welfare Publication (ADM). Rockville: National Institute of Mental Health; 1976. p. 218\u2013222."},{"key":"3009_CR42","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","volume":"133","author":"RC Young","year":"1978","unstructured":"Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429\u201335.","journal-title":"Br J Psychiatry"},{"key":"3009_CR43","doi-asserted-by":"publisher","unstructured":"Cao B, Park C, Subramaniapillai M, et al. The efficacy of vortioxetine on anhedonia in patients with major depressive disorder. Front Psychiatry. 2019;10:17. https:\/\/doi.org\/10.3389\/fpsyt.2019.00017.","DOI":"10.3389\/fpsyt.2019.00017"},{"key":"3009_CR44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jad.2021.12.105","volume":"300","author":"W Zheng","year":"2022","unstructured":"Zheng W, Gu LM, Sun CH, et al. Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression. J Affect Disord. 2022;300:109\u201313.","journal-title":"J Affect Disord"},{"key":"3009_CR45","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/NDT.S296451","volume":"17","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Christensen MC. Efficacy of vortioxetine on anhedonia: results from a pooled analysis of short-term studies in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2021;17:575\u201385.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1\u20133","key":"3009_CR46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jad.2006.08.020","volume":"99","author":"IH Franken","year":"2007","unstructured":"Franken IH, Rassin E, Muris P. The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS). J Affect Disord. 2007;99(1\u20133):83\u20139.","journal-title":"J Affect Disord"},{"issue":"6","key":"3009_CR47","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/YIC.0b013e32833eb5ee","volume":"25","author":"PA Nakonezny","year":"2010","unstructured":"Nakonezny PA, Carmody TJ, Morris DW, et al. Psychometric evaluation of the Snaith-Hamilton pleasure scale in adult outpatients with major depressive disorder. Int Clin Psychopharmacol. 2010;25(6):328\u201333.","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"3009_CR48","doi-asserted-by":"crossref","first-page":"20m02611","DOI":"10.4088\/PCC.20m02611","volume":"22","author":"LN Yatham","year":"2020","unstructured":"Yatham LN, Vieta E, McIntyre RS, et al. Broad efficacy of cariprazine on depressive symptoms in bipolar disorder and the clinical implications. Prim Care Companion CNS Disord. 2020;22(5):20m02611.","journal-title":"Prim Care Companion CNS Disord"},{"key":"3009_CR49","doi-asserted-by":"crossref","unstructured":"Whitton AE, Kumar P, Treadway MT, et al. Distinct profiles of anhedonia and reward processing and their prospective associations with quality of life among individuals with mood disorders. Mol Psychiatry. 2023;28(12):5272\u201381.","DOI":"10.1038\/s41380-023-02165-1"},{"issue":"10","key":"3009_CR50","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1017\/S0033291718002441","volume":"49","author":"TA Allen","year":"2019","unstructured":"Allen TA, Lam RW, Milev R, et al. Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. Psychol Med. 2019;49(10):1629\u201338.","journal-title":"Psychol Med"},{"issue":"4","key":"3009_CR51","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1017\/S1092852919001287","volume":"25","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Suppes T, Earley W, et al. Cariprazine efficacy in bipolar\u00a0I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. CNS Spectr. 2020;25(4):502\u201310.","journal-title":"CNS Spectr"},{"issue":"3","key":"3009_CR52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1017\/S109285292200013X","volume":"28","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS, Daniel DG, VIeta E, et al. The efficacy of cariprazine on cognition: a post hoc analysis from phase\u00a0II\/III clinical trials in bipolar mania, bipolar depression, and schizophrenia. CNS Spectr. 2023;28(3):319\u201330.","journal-title":"CNS Spectr"},{"key":"3009_CR53","doi-asserted-by":"crossref","unstructured":"Jain R, McIntyre RS, Cutler AJ, et al. Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: a pooled post hoc analysis. Int Clin Psychopharmacol. 2024;39(2):82\u201392.","DOI":"10.1097\/YIC.0000000000000500"},{"issue":"2","key":"3009_CR54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11920-018-0877-z","volume":"20","author":"S Rizvi","year":"2018","unstructured":"Rizvi S, Lambert C, Kennedy S. Presentation and neurobiology of anhedonia in mood disorders: commonalities and distinctions. Curr Psychiatry Rep. 2018;20(2):13.","journal-title":"Curr Psychiatry Rep"},{"issue":"9","key":"3009_CR55","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1080\/03007995.2021.1932446","volume":"37","author":"E Vieta","year":"2021","unstructured":"Vieta E, Calabrese JR, Whelan J, et al. The efficacy of cariprazine on function in patients with bipolar depression: a post hoc analysis of a randomized controlled trial. Curr Med Res Opin. 2021;37(9):1635\u201343.","journal-title":"Curr Med Res Opin"},{"issue":"19\u201320","key":"3009_CR56","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","volume":"233","author":"RR Girgis","year":"2016","unstructured":"Girgis RR, Slifstein M, D\u2019Souza D, et al. Preferential binding to dopamine\u00a0D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology. 2016;233(19\u201320):3503\u201312.","journal-title":"Psychopharmacology"},{"issue":"10074","key":"3009_CR57","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","volume":"389","author":"G N\u00e9meth","year":"2017","unstructured":"N\u00e9meth G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103\u201313.","journal-title":"Lancet"},{"issue":"1\u20132","key":"3009_CR58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","volume":"124","author":"A Schotte","year":"1996","unstructured":"Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 1996;124(1\u20132):57\u201373.","journal-title":"Psychopharmacology"},{"key":"3009_CR59","unstructured":"Vraylar [package insert]. Madison, NJ: Allergan; 2022."},{"key":"3009_CR60","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jad.2017.03.032","volume":"215","author":"W Earley","year":"2017","unstructured":"Earley W, Durgam S, Lu K, et al. Tolerability of cariprazine in the treatment of acute bipolar\u00a0I mania: a pooled post hoc analysis of 3 phase\u00a0II\/III studies. J Affect Disord. 2017;215:205\u201312.","journal-title":"J Affect Disord"},{"issue":"6","key":"3009_CR61","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/YIC.0000000000000187","volume":"32","author":"W Earley","year":"2017","unstructured":"Earley W, Laszlovszky I, Debelle M, et al. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase\u00a0II\/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2017;32(6):319\u201328.","journal-title":"Int Clin Psychopharmacol"},{"key":"3009_CR62","doi-asserted-by":"publisher","unstructured":"Thase ME, Yeung PP, Rekeda L, et al. Safety and tolerability of cariprazine for the adjunctive treatment of major depressive disorder: a pooled analysis of phase\u00a02b\/phase\u00a03 clinical trials. Int Clin Psychopharmacol. 2024. https:\/\/doi.org\/10.1097\/YIC.0000000000000528.","DOI":"10.1097\/YIC.0000000000000528"},{"key":"3009_CR63","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/DDDT.S95100","volume":"10","author":"T Nakamura","year":"2016","unstructured":"Nakamura T, Kubota T, Iwakaji A, et al. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther. 2016;10:327\u201338.","journal-title":"Drug Des Devel Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03009-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03009-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03009-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:03:23Z","timestamp":1738235003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03009-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3009"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03009-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Roger S. McIntyre has received research grant support from the Canadian Institute of Health Research (CIHR), Global Alliance for Chronic Diseases (GACD), Milken Institute, and the National Natural Science Foundation of China (NSFC); has received speaker\/consultation fees from AbbVie, Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Boehringer Ingelheim, Eisai, Janssen, Kris, Intra-Cellular, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, NewBridge Pharmaceuticals, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris; is a CEO of Braxia Scientific Corp. Roger S. McIntyre is an Editorial Board member of Advances in Therapy. Roger S. McIntyre was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Pierre-Michel Llorca has participated in advisory boards for Eisai, Ethypharm, Janssen, Lundbeck, MSD, Neuraxpharm, Novartis, Otsuka, Roche, and Rovi; has received speaker\u2019s honoraria and consultation fees from AbbVie, Eisai, Ethypharm, Janssen, Lundbeck, MSD, Neuraxpharm, Novartis, Otsuka, Roche, and Rovi; is member of the Executive Committee of Fondation FondaMental; and has been involved in developing National Care Guidelines for the French Society for Biological Psychiatry and Neuropsychopharmacology on the treatment of major depression. Lauren C. Aronin, Jun Yu, and Huy-Binh Nguyen are employees of AbbVie and may hold stock.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"No prospective data were collected during this post hoc analysis and therefore ethical approval was not required. During the original trials, all study protocols complied with the Declaration of Helsinki and Good Clinical Practice guidelines and were approved by an institutional review board (US centers) or an ethics committee\/government agency (non-US centers). Written informed consent was obtained from all patients included in the trials.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}